Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.12 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
49 50 Next >
2 Reasons to Buy AbbVie Stock and 1 Reason to Sell
The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem. 
Via The Motley Fool
Southwest Gas, Albemarle, Bristol-Myers Squibb And This Fintech Play On CNBC's 'Final Trades'
On CNBC’s “Halftime Report Final Trades,” Karen Firestone of Aureus Asset Management said HealthEquity Inc. (NASDAQ: HQY) is “a stock that provides leadership in the health savings plan” segment. 
Via Benzinga
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result... 
Via Benzinga
Credit Suisse Sees Uncertainty On New Product Launch Execution & Growth For Bristol Myers
Via Benzinga
Where Bristol-Myers Squibb Stands With Analysts
Via Benzinga
8 Analysts Have This to Say About Bristol-Myers Squibb
Via Benzinga
2 Ultra-Safe Passive Income Stocks to Buy Right Now
These two top biopharma stocks are crushing the 2022 bear market. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Upgrades 
Via Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has risen 8.33% since its last report. The company recently reported that it has 24.77 million shares sold short, which is 1.17% of all regular... 
Via Benzinga
2 Stocks to Buy Whether or Not a Recession Is Coming
Both have outperformed the stock market this year. 
Via The Motley Fool
OncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin Cancer
Via Benzinga
JPMorgan Chase, Bristol-Myers Squibb And 3 Other Stocks Insiders Are Selling
US crude oil futures traded lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Why Are Healthcare Stocks Down Today?
Healthcare stocks are falling after a false tweet from a Twitter account impersonating Eli Lilly. Here's what this news means for investors. 
Via InvestorPlace
Is This Blue-Chip Dividend Stock a Buy?
Shares of this pharmaceutical stock have surged higher in 2022. 
Via The Motley Fool
SELLAS Life Sciences' GPS Combo Therapy Shows Overall Survival Of 18 Months In Pretreated Ovarian Cancer Patients
Via Benzinga
Bristol-Myers Squibb To Surge Over 10%? Plus Morgan Stanley Predicts $263 For L3Harris Technologies
Atlantic Equities boosted the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $85 to $88. Atlantic Equities analyst Steve Chesney maintained the stock with an Overweight. Bristol-Myers... 
Via Benzinga
Buy Bristol-Myers Squibb, Merck, 10-Year Treasury ETF And This Payments Stock: CNBC's 'Final Trades'
On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners chose Bristol-Myers Squibb Co. (NYSE: BMY) as his final trade. 
Via Benzinga
Here's Why This Growth Stock Is Already My 2022 Winner
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter. 
Via The Motley Fool
The 7 Best Pharma Stocks to Buy Now
Investors searching for gains in the current market storm should consider taking a position in some of the best pharma stocks. 
Via InvestorPlace
Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks
Just because the stock market is going haywire doesn't mean you have to sit on the sidelines. 
Via The Motley Fool
US Supreme Court Throws Out Bristol Myers Appeal On Cancer-Drug Related Patent With Gilead
Via Benzinga
A $10,000 Investment at the Start of the Great Recession Would Be Worth This Much Today
Investors should focus on individual businesses -- not economic predictions -- when making investment decisions. 
Via The Motley Fool
How Is The Market Feeling About Bristol-Myers Squibb?
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 4.42% since its last report. The company recently reported that it has 23.08 million shares sold short, which is 1.08% of all regular... 
Via Benzinga
Can Biotech Stocks Continue Rallying In This Bear Market?
Via Talk Markets
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
Via Benzinga
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
By Mark Gilman, Benzinga 
Via News Direct
Exposures Product Safety
Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock
Via Benzinga
Wingstop To Rally Around 13%? Plus This Analyst Cuts PT On Cano Health By 50%
  Wedbush boosted the price target on Wingstop Inc. (NASDAQ: WING) from $157 to $177. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Wingstop shares rose 0.8% to $156.66 on... 
Via Benzinga
If You Invested $10,000 in Bristol Myers Squibb 5 Years Ago, This Is How Much You Would Have Today
The stock has been beating the market this year -- and that says a lot. 
Via The Motley Fool
Where Bristol-Myers Squibb Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Bristol-Myers Squibb (NYSE:BMY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding... 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
49 50 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.